[144] IBEX Ltd SEC Filing

Rhea-AI Filing Summary

IBEX Ltd filed a Form 144 reporting a proposed sale of 6,711 common shares with an aggregate market value of $265,632.78, expected to occur on 10/02/2025 on NASDAQ. The shares were acquired by vesting of a performance grant on 09/30/2025 totaling 14,524 shares. The filing also discloses two recent sales by the same account: 1,634 shares sold on 08/26/2025 for $47,544.08 and 45,027 shares sold on 09/16/2025 for $1,751,100.03. The filer attests there is no undisclosed material adverse information.

Positive

• Proposed sale is disclosed publicly, satisfying Rule 144 notice requirements
• Securities to be sold were acquired by vesting on 09/30/2025, not by undisclosed private transfers

Negative

• Recent large insider sale of 45,027 shares on 09/16/2025 generated $1,751,100.03
• Aggregate recent sales of 46,661 shares in the past three months could increase share supply

Insights

Equity Capital Markets Analyst

TL;DR: Insider plans to sell 6,711 vested shares after recent large disposals.

The filing shows a proposed sale on 10/02/2025 of 6,711 shares valued at $265,632.78, following a 09/30/2025 vesting of 14,524 performance shares. Two prior sales by the same account totaled 46,661 shares for $1,798,644.11 across 08/26/2025 and 09/16/2025.

This pattern is factual disclosure of insider liquidity events; it documents share supply hitting the market but does not state intent beyond the Form 144 notice.

Insider Transactions Specialist

TL;DR: The shares to be sold were recently acquired via a performance grant vesting.

The securities listed for sale were acquired on 09/30/2025 through the vesting of a performance grant totaling 14,524 shares, with 6,711 of those listed for proposed sale. The filing includes historical sale details for the same account which are fully itemized with dates and proceeds.

This filing provides the required transactional record under Rule 144; no additional trading plan or 10b5-1 adoption date is disclosed in the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	GLOBAL SHARES FINANCIAL SERVICES INC. 575 WASHINGTON BLVD FLOOR 9 JERSERY CITY NJ 07310-1616	6711	265632.78	13315077	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	09/30/2025	VESTING OF PERFORMANCE GRANT	ISSUER			14524	09/30/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROBERT THOMAS DECHANT c/o IBEX LIMITED 1717 Pennsylvania Avenue NW, Suite 825 Washington DC 20006	COMMON	08/26/2025	1634	47544.08
ROBERT THOMAS DECHANT c/o IBEX LIMITED 1717 Pennsylvania Avenue NW, Suite 825 Washington DC 20006	COMMON	09/16/2025	45027	1751100.03

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the IBEX (IBEX) Form 144 report?

The filing reports a proposed sale of 6,711 common shares valued at $265,632.78, with acquisition noted as a performance grant vesting on 09/30/2025.

Who sold shares recently according to this filing?

Robert Thomas Dechant (c/o IBEX Limited) sold 1,634 shares on 08/26/2025 for $47,544.08 and 45,027 shares on 09/16/2025 for $1,751,100.03.

When is the proposed sale scheduled?

The proposed sale is listed for 10/02/2025 on NASDAQ.

How were the shares acquired that are being sold?

The shares were acquired via the vesting of a performance grant on 09/30/2025, totaling 14,524 shares.

Does the filer assert any undisclosed material information?

Yes. By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.